placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in This milestone marks a major advance for patients with progressive fibrotic lung disease, expanding treatment options beyond current antifibrotics
Less fermentable fibers like psyllium and methylcellulose typically produce less gas than highly fermentable fibers found in some fruits, legumes, and certain grains
References 1 Abdel WahedW
Aggressive calorie restriction combined with GLP-1 activation can produce excessive energy deficits and fatigue
Amino acids classified as nonessential (produced in the body) are necessary for the health of adult humans, but must be supplemented in the face of various diseases and also during growth
Frequently Asked Questions: Ozempic Class Action Lawsuit 1
